Severity
Low
FDA Drug recall · Reported September 5, 2012
Short Fill: The product is being recalled due to a potential underfill of the affected vials.
Bracco Diagnostics Inc recalled Bracco Diagnostics multihance (gadobenate dimeglumine) injection, 529 mg/mL, 20ml, Rx onl… - a low-severity action.
Bracco Diagnostics multihance (gadobenate dimeglumine) injection, 529 mg/mL, 20ml, Rx onl… was recalled by Bracco Diagnostics Inc in September 5, 2012. Reason: Short Fill: The product is being recalled due to a potential underfill of the affected vials.. Check the official notice for the remedy. Verify recall #D-1663-2012 with the FDA Drug before acting.
The recall
Bracco Diagnostics Inc issued this low-severity FDA Drug recall-Short Fill: The product is being recalled due to a potential underfill of the affected vials..
Sourced from official FDA Drug enforcement records. Verify recall #D-1663-2012 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-1663-2012) was formally reported on September 5, 2012, with the manufacturer initiating the action on April 16, 2012. It is classified under Low severity (Class III), with a current status of Terminated. Bracco Diagnostics Inc is listed as the recalling firm, operating out of Monroe Township, NJ. Federal records list the affected scope as 47,750 vials.
The documented reason for this recall is: Short Fill: The product is being recalled due to a potential underfill of the affected vials. Distribution data in the federal record shows the product reached: Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
47,750 vials
Related Recalls
6
5 from same agency
Bracco Diagnostics multihance (gadobenate dimeglumine) injection, 529 mg/mL, 20ml, Rx only, Manufactured for: Bracco Diagnostics Inc., Princeton, NJ 08543 USA, NDC 0270-5164-15
Short Fill: The product is being recalled due to a potential underfill of the affected vials.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-1663-2012 |
| Date reported | September 5, 2012 |
| Date initiated | April 16, 2012 |
| Recalling firm | Bracco Diagnostics Inc |
| Firm location | Monroe Township, NJ |
| Affected scope | 47,750 vials |
| Distribution | Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported September 5, 2012. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.